These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 29574715)

  • 41. GD2-targeted immunotherapy and potential value of circulating microRNAs in neuroblastoma.
    Gholamin S; Mirzaei H; Razavi SM; Hassanian SM; Saadatpour L; Masoudifar A; ShahidSales S; Avan A
    J Cell Physiol; 2018 Feb; 233(2):866-879. PubMed ID: 28145567
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Anti-GD2 mAbs and next-generation mAb-based agents for cancer therapy.
    Perez Horta Z; Goldberg JL; Sondel PM
    Immunotherapy; 2016 Sep; 8(9):1097-117. PubMed ID: 27485082
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Oral (1-->3),(1-->4)-beta-D-glucan synergizes with antiganglioside GD2 monoclonal antibody 3F8 in the therapy of neuroblastoma.
    Cheung NK; Modak S
    Clin Cancer Res; 2002 May; 8(5):1217-23. PubMed ID: 12006541
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A transplantable TH-MYCN transgenic tumor model in C57Bl/6 mice for preclinical immunological studies in neuroblastoma.
    Kroesen M; Nierkens S; Ansems M; Wassink M; Orentas RJ; Boon L; den Brok MH; Hoogerbrugge PM; Adema GJ
    Int J Cancer; 2014 Mar; 134(6):1335-45. PubMed ID: 24038106
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Phase I trial of a bivalent gangliosides vaccine in combination with β-glucan for high-risk neuroblastoma in second or later remission.
    Kushner BH; Cheung IY; Modak S; Kramer K; Ragupathi G; Cheung NK
    Clin Cancer Res; 2014 Mar; 20(5):1375-82. PubMed ID: 24520094
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Long-term follow-up of neuroblastoma in children less than 18 months of age].
    Zhao J; Pan C; Xu M; Zhou M; Gao YJ; Hu WT; Tang JY
    Zhonghua Er Ke Za Zhi; 2017 Oct; 55(10):754-759. PubMed ID: 29050113
    [No Abstract]   [Full Text] [Related]  

  • 47. Immunotherapy with anti-G
    Kushner BH; Modak S; Kramer K; Basu EM; Iglesias-Cardenas F; Roberts SS; Cheung NV
    Int J Cancer; 2023 Jan; 152(2):259-266. PubMed ID: 35913764
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma.
    Yu AL; Gilman AL; Ozkaynak MF; London WB; Kreissman SG; Chen HX; Smith M; Anderson B; Villablanca JG; Matthay KK; Shimada H; Grupp SA; Seeger R; Reynolds CP; Buxton A; Reisfeld RA; Gillies SD; Cohn SL; Maris JM; Sondel PM;
    N Engl J Med; 2010 Sep; 363(14):1324-34. PubMed ID: 20879881
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Hypothyroidism after 131I-monoclonal antibody treatment of neuroblastoma.
    Bhandari S; Cheung NK; Kushner BH; Kramer K; Modak S; Larson SM; Yeh S; Heller G; Sklar CA
    Pediatr Blood Cancer; 2010 Jul; 55(1):76-80. PubMed ID: 20213847
    [TBL] [Abstract][Full Text] [Related]  

  • 50. FCGR2A polymorphism is correlated with clinical outcome after immunotherapy of neuroblastoma with anti-GD2 antibody and granulocyte macrophage colony-stimulating factor.
    Cheung NK; Sowers R; Vickers AJ; Cheung IY; Kushner BH; Gorlick R
    J Clin Oncol; 2006 Jun; 24(18):2885-90. PubMed ID: 16682723
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Polymorphonuclear myeloid-derived suppressor cells impair the anti-tumor efficacy of GD2.CAR T-cells in patients with neuroblastoma.
    Tumino N; Weber G; Besi F; Del Bufalo F; Bertaina V; Paci P; Quatrini L; Antonucci L; Sinibaldi M; Quintarelli C; Maggi E; De Angelis B; Locatelli F; Moretta L; Vacca P; Caruana I
    J Hematol Oncol; 2021 Nov; 14(1):191. PubMed ID: 34772439
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A phase I/IB trial of murine monoclonal anti-GD2 antibody 14.G2a plus interleukin-2 in children with refractory neuroblastoma: a report of the Children's Cancer Group.
    Frost JD; Hank JA; Reaman GH; Frierdich S; Seeger RC; Gan J; Anderson PM; Ettinger LJ; Cairo MS; Blazar BR; Krailo MD; Matthay KK; Reisfeld RA; Sondel PM
    Cancer; 1997 Jul; 80(2):317-33. PubMed ID: 9217046
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Comparison of pain outcomes between two anti-GD2 antibodies in patients with neuroblastoma.
    Anghelescu DL; Goldberg JL; Faughnan LG; Wu J; Mao S; Furman WL; Santana VM; Navid F
    Pediatr Blood Cancer; 2015 Feb; 62(2):224-228. PubMed ID: 25382742
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Advances in Anti-GD2 Immunotherapy for Treatment of High-risk Neuroblastoma.
    Voeller J; Sondel PM
    J Pediatr Hematol Oncol; 2019 Apr; 41(3):163-169. PubMed ID: 30897608
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Curability of recurrent disseminated disease after surgery alone for local-regional neuroblastoma using intensive chemotherapy and anti-G(D2) immunotherapy.
    Kushner BH; Kramer K; LaQuaglia MP; Cheung NK
    J Pediatr Hematol Oncol; 2003 Jul; 25(7):515-9. PubMed ID: 12847316
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Early molecular response of marrow disease to biologic therapy is highly prognostic in neuroblastoma.
    Cheung IY; Lo Piccolo MS; Kushner BH; Cheung NK
    J Clin Oncol; 2003 Oct; 21(20):3853-8. PubMed ID: 14551304
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The GD2-specific 14G2a monoclonal antibody induces apoptosis and enhances cytotoxicity of chemotherapeutic drugs in IMR-32 human neuroblastoma cells.
    Kowalczyk A; Gil M; Horwacik I; Odrowaz Z; Kozbor D; Rokita H
    Cancer Lett; 2009 Aug; 281(2):171-82. PubMed ID: 19339105
    [TBL] [Abstract][Full Text] [Related]  

  • 58. KIR3DL1 Allelic Polymorphism and HLA-B Epitopes Modulate Response to Anti-GD2 Monoclonal Antibody in Patients With Neuroblastoma.
    Forlenza CJ; Boudreau JE; Zheng J; Le Luduec JB; Chamberlain E; Heller G; Cheung NK; Hsu KC
    J Clin Oncol; 2016 Jul; 34(21):2443-51. PubMed ID: 27069083
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Neuroblastoma: Therapeutic strategies for a clinical enigma.
    Modak S; Cheung NK
    Cancer Treat Rev; 2010 Jun; 36(4):307-17. PubMed ID: 20227189
    [TBL] [Abstract][Full Text] [Related]  

  • 60. 3F8 monoclonal antibody treatment of patients with stage IV neuroblastoma: a phase II study.
    Cheung NK; Kushner BH; Yeh SJ; Larson SM
    Prog Clin Biol Res; 1994; 385():319-28. PubMed ID: 7972227
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.